期刊
CANCER
卷 124, 期 24, 页码 4592-4596出版社
WILEY
DOI: 10.1002/cncr.31681
关键词
-
类别
资金
- National Institutes of Health/National Cancer Institute [P50 CA196530-01]
- Department of Defense Lung Cancer Research Program Career Development Award
Recent trials have demonstrated that the addition of a programmed cell death protein 1 inhibitor to chemotherapy in the first-line setting in patients with metastatic squamous or nonsquamous non-small cell lung cancer improves survival compared with chemotherapy alone. These findings provide a new treatment option for patients with newly diagnosed, advanced non-small cell lung cancer, regardless of tumor histology or programmed death-ligand 1 expression, thereby representing a major advancement in the field.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据